The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.

@article{Awni1995ThePA,
  title={The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.},
  author={Walid M. Awni and Rene A. Braeckman and John H. Cavanaugh and Charles S. Locke and P J Linnen and G. Richard Granneman and Louise M. Dub{\'e}},
  journal={Clinical pharmacokinetics},
  year={1995},
  volume={29 Suppl 2},
  pages={
          112-24
        }
}
The potential pharmacokinetic and pharmacodynamic interactions between zileuton, a 5-lipoxygenase inhibitor, and naproxen, a nonsteroidal anti-inflammatory drug that acts as a cyclo-oxygenase inhibitor, have been investigated in 24 healthy volunteers. Coadministration of these 2 drugs had no effect upon the plasma concentration-time curves of either zileuton (800mg) or naproxen (500mg) when compared with each drug administered alone. Both naproxen plasma concentrations during the elimination… CONTINUE READING